Dietary Supplement GMP Warning Letters
This article was originally published in The Tan Sheet
Dietary supplement manufacturers’ responses to FDA reports of good manufacturing practices problems not only are inadequate, but in some instances prompt the agency to warn of checking for corrective actions in later inspections, according to recently posted warning letters.
You may also be interested in...
Dietary supplement and food product firms will not incur user fees for facility or import re-inspections or mandatory recalls until FDA establishes a waiver process for small businesses.
About one-third of the 90 dietary supplement good manufacturing practices inspections FDA completed in fiscal 2010 by the start of September revealed serious compliance problems, according to Principal Deputy Commissioner Josh Sharfstein
Teva will not engage in paragraph IV patent-infringement litigation with Evoke Pharma over the originator’s Gimoti (metoclopramide) nasal spray treatment for diabetic gastroparesis, following a court order.